INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5801, 4689, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5802, 8037, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5803, 22352, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5804, 22604, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5805, 22606, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5806, 22607, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5807, 22608, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5808, 22823, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5809, 22824, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5810, 23591, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5811, 30112, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5812, 30113, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5813, 30911, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5814, 33711, 'Meropenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5815, 1611, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5816, 4689, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5817, 8037, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5818, 22352, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5819, 22604, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5820, 22606, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5821, 22607, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5822, 22608, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5823, 22823, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5824, 22824, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5825, 23591, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5826, 30112, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5827, 30113, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5828, 30911, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5829, 33711, 'Meropenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5830, 1611, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5831, 4689, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5832, 8037, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5833, 22352, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5834, 22604, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5835, 22606, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5836, 22607, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5837, 22608, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5838, 22823, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5839, 22824, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5840, 23591, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5841, 30112, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5842, 30113, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5843, 30911, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5844, 33711, 'Meropenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5845, 1611, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5846, 4689, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5847, 8037, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5848, 22352, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5849, 22604, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5850, 22606, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5851, 22607, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5852, 22608, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5853, 22823, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5854, 22824, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5855, 23591, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5856, 30112, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5857, 30113, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5858, 30911, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5859, 33711, 'Meropenem', 'Heart Failure', 'Parenteral meropenem is formulated with sodium carbonate to adjust the pH of the reconstituted solution and contains 90.2 mg (3.92 mEq) of sodium per each gram of meropenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5860, 0, 'Menotropins', 'Thromboembolism', 'Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome.  Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5861, 0, 'Menotropins', 'Thyroid Diseases', 'The use of menotropins is contraindicated in patients with uncontrolled non- gonadal endocrinopathies such as thyroid, adrenal or pituitary disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5862, 0, 'Menotropins', 'Central Nervous System Neoplasms', 'The use of menotropins is contraindicated in patients with CNS lesions, such as pituitary gland or hypothalamus tumors.  Menotropins possess LH and FSH activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5863, 0, 'Menotropins', 'Uterine Hemorrhage', 'The use of menotropins is contraindicated in female patients with abnormal vaginal bleeding of undetermined origin.  Patients should be evaluated to ensure neoplastic lesions are not present.  The use of menotropins is contraindicated in the presence of sex hormone dependent tumors of the reproductive tract or accessory organs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5864, 0, 'Menotropins', 'Lung Diseases', 'Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins.  Caution and monitoring is advised if used in women with pulmonary conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5865, 0, 'Menotropins', 'Liver Failure', 'Safety, efficacy and pharmacokinetics of menotropins have not been established in women with renal or hepatic insufficiency.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5866, 25505, 'Mercaptopurine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5867, 25505, 'Mercaptopurine', 'Liver Diseases', 'Mercaptopurine is hepatotoxic.  Hepatic injury can occur at any dosage, however, increased frequency of injury occurs when doses exceed 2.5 mg/kg/day.  Deaths due to hepatic necrosis have been reported.   Patients should be instructed to immediately report any signs of hepatotoxicity such as jaundice, hepatic dysfunction such as, jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with mercaptopurine should be administered cautiously in patients with or predisposed to compromised hepatic function.  Clinical monitoring of hepatic function and determination of the etiology of hepatic dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5868, 25505, 'Mercaptopurine', 'Bone Marrow Failure Disorders', 'Mercaptopurine induces dose-related myelosuppression which can be delayed.  Leukopenia, thrombocytopenia, and anemia have been reported during mercaptopurine therapy.  Therapy should be administered cautiously in patients with myelosuppression and therapy should be withheld at the first indication of an abnormally large reduction of any bone marrow element.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5869, 25505, 'Mercaptopurine', 'Thiopurine S methyltranferase deficiency', 'Thioguanine is closely related structurally and functionally to mercaptopurine.  A rare deficiency in the enzyme thiopurine methyltransferase (TMPT) results in an increased sensitivity to the myelosuppressive effects of both drugs causing rapid bone marrow suppression following initial mercaptopurine or thioguanine administration.  Therapy with thioguanine or mercaptopurine should be administered cautiously and at a reduced dose in patients with TMPT deficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5870, 25505, 'Mercaptopurine', 'Kidney Diseases', 'Mercaptopurine is excreted in the urine as unchanged drug and metabolites.  Renal elimination may be reduced in patients with impaired renal function.  Therapy with mercaptopurine should be initiated at a reduced dosage in patients with compromised renal function.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5871, 0, 'Ardeparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5872, 0, 'Ardeparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5873, 0, 'Ardeparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5874, 0, 'Ardeparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5875, 0, 'Ardeparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5876, 0, 'Ardeparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5877, 0, 'Ardeparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5878, 0, 'Ardeparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5879, 0, 'Ardeparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5880, 0, 'Ardeparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5881, 473, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5882, 475, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5883, 476, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5884, 478, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5885, 479, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5886, 7923, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5887, 7924, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5888, 16720, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5889, 16721, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5890, 16722, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5891, 17206, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5892, 17207, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5893, 17243, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5894, 18026, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5895, 22273, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5896, 22513, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5897, 22514, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5898, 22516, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5899, 24668, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5900, 25735, 'Memantine', 'Hepatic Insufficiency', 'Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
